ClinicalTrials.gg
CompletedNCT01669811Updated Aug 27, 2015Results posted

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

A Phase 3 interventional study of Esomeprazole (D961H) twice daily and Esomeprazole (D961H) once daily in Refractory Reflux Esophagitis, sponsored by AstraZeneca. Completed at 63 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,398
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.

Started
2012
with 1 other
Phase 3
5 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is one of 2 that started in 2012, is one of 5 in phase 3, and was the 8th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →

Where they have run

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis, Peptic by AstraZeneca as a file.
02

Study summary

This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of esomeprazole magnesium salt) with refractory reflux esophagitis after 8 weeks of standard Proton-pump inhibitor (PPI) therapy by assessment of presence/absence of inflammation (esophagitis) at Week 8 according to the Los Angeles (LA) classification

Read the detailed description

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg twice daily oral administration and D961H 20 mg once daily oral administration in patients with refractory reflux esophagitis

03

Conditions studied

  • Refractory Reflux Esophagitis

Browse trials for

Keywords

  • Refractory Reflux Esophagitis,
  • Japanese,
  • Nexium,
  • twice daily,
  • oral administration
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Patients with RE classified into LA classification Grade A, B, C or D by Endoscopy despite of at least 8-week treatment using standard doses of PPIs.
  3. Patients must fulfill at least one of the following criteria such as (i) RE with LA grade C/D at Endoscopy on visit 1 and/or history of RE with LA grade C/D, (ii) RE was diagnosed more than 1 year before visit 1.
  4. Patients who are able to complete the Patient Diary

Exclusion criteria

Exclusion Criteria:

  1. Male or female aged less than 20 years at the time of .
  2. Patients with current evidence of the gastrointestinal diseases/conditions such as esophageal stricture to interfere with the evaluation of the study etc
  3. Gastric or duodenal ulcer verified by Endoscopy within 12 weeks before randomisation.
  4. Previous esophageal, gastric or duodenal surgery except simple closure of perforated ulcer, simple endoscopic treatment with simple operation etc
  5. Current or historical evidence (within 12 weeks prior to randomisation) of the diseases/conditions as judged to interfere with the evaluation of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,398 participants (actual)

Study arms

  • Experimental
    D961H 20mg twice daily

    Double-blinded

    Drug: Esomeprazole (D961H) twice daily

  • Active comparator
    D961H 20mg once daily

    Double-blinded

    Drug: Esomeprazole (D961H) once daily

Interventions

  • DrugEsomeprazole (D961H) twice daily

    One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening

  • DrugEsomeprazole (D961H) once daily

    One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification

    Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 8 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification

    Time frame: 8 Weeks

Secondary outcomes

  1. Percentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification

    Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 4 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification

    Time frame: 4 Weeks

  2. Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4

    Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -heartburn at Week 4 (on Day 29) based on the Kaplan-Meier method.

    Time frame: 4 Weeks

  3. Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4

    Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -acid regurgitation at Week 4 (on Day 29) based on the Kaplan-Meier method.

    Time frame: 4 Weeks

  4. Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4

    Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -abdominal pain at Week 4 (on Day 29) based on the Kaplan-Meier method.

    Time frame: 4 Weeks

  5. Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4

    Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -difficulty of swallowing at Week 4 (on Day 29) based on the Kaplan-Meier method.

    Time frame: 4 Weeks

  6. Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4

    Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -sleep disturbance at Week 4 (on Day 29) based on the Kaplan-Meier method.

    Time frame: 4 Weeks

07

Results

Posted Aug 14, 2015

Participant flow

First subject enrolled on 25 August 2012. Last subject completed on 30 May 2014.

Participant flow — Overall Study
MilestoneD961H 20 mg BIDD961H 20 mg QD + Placebo
Started145142
Completed142131
Not completed311
Withdrew: Investigator decision01
Withdrew: Withdrawal by subject12
Withdrew: Adverse event26
Withdrew: Eligibility criteria not fulfilled02

Outcome measures

PrimaryPercentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification

Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 8 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification

Time frame:
8 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification92.4 (86.9 to 95.7)68.6 (60.5 to 75.7)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Chi-squared · p = <0.0001 (p-value is obtained using chi square method.) · Difference in proportions: 23.8 · 95% CI 14.9 to 32.695% CI is obtained using Newcombe-Wilson score method without continuity correction.
SecondaryPercentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification

Percentage of participants with healing of reflux esophagitis (RE) who were graded "O" (No RE) at Week 4 out of participants who were graded "A" (least severe) to "D" (most severe) at baseline according to Los Angeles classification

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Percentage of Participants With Healing of RE Who Were Graded "O" at Week 4 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles Classification81.4 (74.3 to 86.9)48.6 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Chi-squared · p = <0.0001 (p-value is obtained using chi square method.) · Difference in proportions: 32.8 · 95% CI 21.9 to 42.695% CI is obtained using Newcombe-Wilson score method without continuity correction.
SecondaryCumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4

Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -heartburn at Week 4 (on Day 29) based on the Kaplan-Meier method.

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 481.1 (74.3 to 86.9)72.8 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Log Rank · p = 0.1452 · Hazard ratio (hr): 1.29 · 95% CI 0.91 to 1.8395% CI of the hazard ratio is obtained using Cox proportional hazards model including a factor of treatment group.
SecondaryCumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4

Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -acid regurgitation at Week 4 (on Day 29) based on the Kaplan-Meier method.

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 473.1 (74.3 to 86.9)61.2 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Log Rank · p = 0.0837 · Hazard ratio (hr): 1.46 · 95% CI 0.97 to 2.1895% CI of the hazard ratio is obtained using Cox proportional hazards model including a factor of treatment group.
SecondaryCumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4

Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -abdominal pain at Week 4 (on Day 29) based on the Kaplan-Meier method.

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 468.1 (74.3 to 86.9)59.1 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Log Rank · p = 0.2678 · Hazard ratio (hr): 1.34 · 95% CI 0.80 to 2.2695% CI of the hazard ratio is obtained using Cox proportional hazards model including a factor of treatment group.
SecondaryCumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4

Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -difficulty of swallowing at Week 4 (on Day 29) based on the Kaplan-Meier method.

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 478.6 (74.3 to 86.9)74.1 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Log Rank · p = 0.6389 · Hazard ratio (hr): 1.15 · 95% CI 0.62 to 2.1295% CI of the hazard ratio is obtained using Cox proportional hazards model including a factor of treatment group.
SecondaryCumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4

Cumulative percentage of participants who had sustained resolution (defined as at least 7-day consecutive symptom free) of gastroesophageal reflux disease (GERD) symptom -sleep disturbance at Week 4 (on Day 29) based on the Kaplan-Meier method.

Time frame:
4 Weeks
Reported as:
Number · Percentage of participants
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4
Percentage of participantsD961H 20mg BidD961H 20mg QD + Placebo
Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 491.2 (74.3 to 86.9)89.3 (40.4 to 56.8)
Statistical analysis
  • D961H 20mg Bid vs D961H 20mg QD + Placebo · Log Rank · p = 0.4485 · Hazard ratio (hr): 1.38 · 95% CI 0.80 to 2.3895% CI of the hazard ratio is obtained using Cox proportional hazards model including a factor of treatment group.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D961H 20 mg BID—1/145 (0.7%)8/145 (5.5%)
D961H 20 mg QD + Placebo—3/142 (2.1%)9/142 (6.3%)
Most frequent serious events
Most frequent serious events
EventD961H 20 mg BIDD961H 20 mg QD + Placebo
GastritisGastrointestinal disorders0/1451/142
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1451/142
Parotid abscessInfections and infestations0/1451/142
Pancreatic pseudocystGastrointestinal disorders1/1450/142
Most frequent other events
Most frequent other events
EventD961H 20 mg BIDD961H 20 mg QD + Placebo
NasopharyngitisInfections and infestations8/1459/142

Baseline characteristics

It was found that 2 patients in D961H 20 mg QD + Placebo group had no refractory RE after randomisation. Therefore, these two patients were excluded from the full analysis set, which was the primary analysis set of this study and was used for summaries of baseline characteristics and outcome measures.

Age, Continuous
Age, Continuous(Years)D961H 20 mg BIDD961H 20 mg QD + PlaceboTotal
Mean64.7 ± 13.8761.7 ± 14.7263.2 ± 14.35
Age, Customized
Age, Customized(Participants)D961H 20 mg BIDD961H 20 mg QD + PlaceboTotal
<656869137
>=657771148
Sex: Female, Male
Sex: Female, Male(Participants)D961H 20 mg BIDD961H 20 mg QD + PlaceboTotal
Female6970139
Male7670146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)D961H 20 mg BIDD961H 20 mg QD + PlaceboTotal
Asian145140285
08

Study locations

63 sites
  • Research Site
    Abiko-shi, Japan
  • Research Site
    Adachi-ku, Japan
  • Research Site
    Annaka-shi, Japan
  • Research Site
    Asahikawa-shi, Japan
  • Research Site
    Asakura-shi, Japan
  • Research Site
    Beppu-shi, Japan
  • Research Site
    Bunkyo-ku, Japan
  • Research Site
    Chuo-ku, Japan
  • Research Site
    Fujiidera-shi, Japan
  • Research Site
    Fukuoka-shi, Japan
  • Research Site
    Fukushima-shi, Japan
  • Research Site
    Gifu-shi, Japan
  • Research Site
    Hamamatsu-shi, Japan
  • Research Site
    Hirakata-shi, Japan
  • Research Site
    Hitachi-shi, Japan
  • Research Site
    Ibara-shi, Japan
  • Research Site
    Ichiki-Kushikino-shi, Japan
  • Research Site
    Ishikari-shi, Japan
  • Research Site
    Iwata-shi, Japan
  • Research Site
    Izumo-shi, Japan
  • Research Site
    Kagoshima-shi, Japan
  • Research Site
    Kamakura-shi, Japan
  • Research Site
    Kanazawa-shi, Japan
  • Research Site
    Karatsu-shi, Japan
  • Research Site
    Kawasaki-shi, Japan
  • Research Site
    Kirishima-shi, Japan
  • Research Site
    Kita-ku, Japan
  • Research Site
    Kobe-shi, Japan
  • Research Site
    Kochi-shi, Japan
  • Research Site
    Koga-shi, Japan
  • Research Site
    Koriyama-shi, Japan
  • Research Site
    Kumagaya-shi, Japan
  • Research Site
    Kumamoto-shi, Japan
  • Research Site
    Kyoto-shi, Japan
  • Research Site
    Machida-shi, Japan
  • Research Site
    Matsumoto-shi, Japan
  • Research Site
    Meguro-ku, Japan
  • Research Site
    Moriguchi-shi, Japan
  • Research Site
    Nishinomiya-shi, Japan
  • Research Site
    Ogori-shi, Japan
  • Research Site
    Oita-shi, Japan
  • Research Site
    Okayama-shi, Japan
  • Research Site
    Osaka-shi, Japan
  • Research Site
    Ota-ku, Japan
  • Research Site
    Otawara-shi, Japan
  • Research Site
    Saga-shi, Japan
  • Research Site
    Saitama-shi, Japan
  • Research Site
    Sakaide-shi, Japan
  • Research Site
    Saku-shi, Japan
  • Research Site
    Sapporo-shi, Japan
  • Research Site
    Sendai-shi, Japan
  • Research Site
    Shibuya-ku, Japan
  • Research Site
    Shinagawa-ku, Japan
  • Research Site
    Shinjuku-ku, Japan
  • Research Site
    Takasaki-shi, Japan
  • Research Site
    Takatsuki-shi, Japan
  • Research Site
    Toshima-ku, Japan
  • Research Site
    Toyama-shi, Japan
  • Research Site
    Uji-shi, Japan
  • Research Site
    Wakayama-shi, Japan
  • Research Site
    Yanagawa-shi, Japan
  • Research Site
    Yokohama-shi, Japan
  • Research Site
    Yufu-shi, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2012
First posted
Aug 21, 2012
Start
Aug 2012
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Aug 14, 2015
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01669811
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 21, 2012
Start date
Aug 2012
Primary completion
May 2014
Completion
May 2014
Results posted
Aug 14, 2015
Last update
Aug 27, 2015

Study contacts

Tore Lind, MSD
study director · AstraZeneca, Moelndal, Sweden
Lan Chen
study director · AstraZeneca, Osaka, Japan
Yoshikazu Kinoshita, PROFESSOR OF MEDICINE
principal investigator · Dept of Gastroenterology and Hepatology, Shimane, Japan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion